Deuterated Drug Purchase Agreement Continues to Validate Deuterium’s Growing Role in the Future of Medicine

The global pharmaceutical industry has been advanced significantly by Vertex [NASDAQ: VRTX] and their potential improvement for the treatment of cystic fibrosis via the use of a novel deuterated drug CTP-656. Vertex’s stock increased a record amount, boosting their market cap by 8 billion USD with shares up 24% after the company shared their data from clinical studies of triple combinations of drug treatments.

For more information on where to buy deuterium oxide, please click the link.

http://investors.vrtx.com/releasedetail.cfm?releaseid=1034371

http://www.marketwatch.com/story/vertex-shares-soar-24-to-all-time-high-on-cystic-fibrosis-drug-studies-2017-07-18